Sacubitril-valsartan for Heart Failure
This trial is testing a new heart failure medication in young adult cancer survivors.
- Heart Failure
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment still available for participants of this research?
"According to clinicaltrials.gov, this research endeavour is actively signing up participants; it was originally posted on March 9th 2022 and recently updated on May 6th 2022."
In what medical conditions is Sacubitril-valsartan most commonly prescribed?
"Sacubitril-valsartan is typically prescribed to treat certain types of ventricular dysfunction, as well as essential hypertension that cannot be successfully managed using a single therapy. It can also serve prophylactically against cardiovascular events."
Is participation in this medical study open to those under the age of 25?
"To be eligible for this research, potential participants must fall between the age of 18 and 120. Concomitantly, 23 clinical trials are available to those under 18 years old, while 720 studies can accomodate individuals over 65."
What is the current participation rate of this research project?
"Indeed, according to the clinicaltrials.gov website, this medical trial is still in need of volunteers. It was first advertised on March 9th 2022 and has been recently updated as of May 6th 2022. The study requires 30 individuals from one location."
What criteria must be fulfilled to join this medical research trial?
"The requirements for admission into this heart failure trial necessitate that patients are between 18 and 120 years old. The investigators hope to admit a total of 30 individuals."
Have researchers conducted any prior research into the efficacy of Sacubitril-valsartan?
"At present, there are 37 studies being conducted pertaining to Sacubitril-valsartan. Of those active clinical trials, 8 have reached phase 3 status. While a majority of these investigations can be found in Montreal, Quebec, global participation serves as a testament to the reach and efficacy of this medication with 826 sites running related experiments."